347 related articles for article (PubMed ID: 25576932)
1. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
Battella S; Cox MC; Santoni A; Palmieri G
J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
[No Abstract] [Full Text] [Related]
6. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
7. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
9. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
Iannello A; Ahmad A
Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer.
Gül N; van Egmond M
Cancer Res; 2015 Dec; 75(23):5008-13. PubMed ID: 26573795
[TBL] [Abstract][Full Text] [Related]
11. Targeting innate immune pathways in cancer immunotherapy: state of the art.
Mastellos DC
J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Antibodies Can Drive Therapeutic T Cell Responses.
Wittrup KD
Trends Cancer; 2017 Sep; 3(9):615-620. PubMed ID: 28867165
[TBL] [Abstract][Full Text] [Related]
13. Combination strategies to enhance antitumor ADCC.
Kohrt HE; Houot R; Marabelle A; Cho HJ; Osman K; Goldstein M; Levy R; Brody J
Immunotherapy; 2012 May; 4(5):511-27. PubMed ID: 22642334
[TBL] [Abstract][Full Text] [Related]
14. Can calcium signaling be harnessed for cancer immunotherapy?
Rooke R
Biochim Biophys Acta; 2014 Oct; 1843(10):2334-40. PubMed ID: 24524821
[TBL] [Abstract][Full Text] [Related]
15. Modulation of tumor immunity by therapeutic monoclonal antibodies.
Abès R; Teillaud JL
Cancer Metastasis Rev; 2011 Mar; 30(1):111-24. PubMed ID: 21267767
[TBL] [Abstract][Full Text] [Related]
16. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
17. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
18. New perspectives on complement mediated immunotherapy.
Stasiłojć G; Österborg A; Blom AM; Okrój M
Cancer Treat Rev; 2016 Apr; 45():68-75. PubMed ID: 26994325
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
Houot R; Kohrt HE; Marabelle A; Levy R
Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
[TBL] [Abstract][Full Text] [Related]
20. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
